Clinical Trial Update: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in Japan evaluating 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer is sponsored by Novartis and currently not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING